3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Ovarian Neoplasms
9
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Sunitinib
27
Nivolumab
26
pembrolizumab
23
Sorafenib
17
Everolimus
14
Cyclophosphamide
13
Interleukin-2
10
Bevacizumab
10
Radiosurgery
9
spartalizumab
8
pazopanib
7
atezolizumab
7
Ipilimumab
7
Axitinib
7
fludarabine
6
aldesleukin
6
cabozantinib
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Immunohistochemistry
5
Gemcitabine
5
peginterferon alfa-2b
4
avelumab
4
Nephrectomy
4
Irinotecan
4
Introns
4
Gene Expression Profiling
4
Capecitabine
4
lenvatinib
3
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Renal Cell
×
niraparib
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled